MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/gutjnl-2018-317725

Медицинская библиотека · Gut · 2019

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.

Zhang Tian-Ying, Guo Xue-Ran, Wu Yang-Tao, Kang Xiao-Zhen, Zheng Qing-Bing, Qi Ruo-Yao, Chen Bin-Bing, Lan Ying, Wei Min, Wang Shao-Juan, Xiong Hua-Long, Cao Jia-Li, Zhang Bao-Hui, Qiao Xiao-Yang, Huang Xiao-Fen, Wang Ying-Bin, Fang Mu-Jin, Zhang Ya-Li, Cheng Tong, Chen Yi-Xin, Zhao Qin-Jian, Li Shao-Wei, Ge Sheng-Xiang, Chen Pei-Jer, Zhang Jun, Yuan Quan, Xia Ning-Shao

Оценочное исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

This study aimed to develop a novel therapeutic vaccine based on a unique B cell epitope and investigate its therapeutic potential against chronic hepatitis B (CHB) in animal models.

METHODS

A series of peptides and carrier proteins were evaluated in HBV-tolerant mice to obtain an optimised therapeutic molecule. The immunogenicity, therapeutic efficacy and mechanism of the candidate were investigated systematically.

RESULTS

Among the HBsAg-aa119-125-containing peptides evaluated in this study, HBsAg-aa113-135 (SEQ13) exhibited the most striking therapeutic effects. A novel immunoenhanced virus-like particle carrier (CR-T3) derived from the roundleaf bat HBV core antigen (RBHBcAg) was created and used to display SEQ13, forming candidate molecule CR-T3-SEQ13. Multiple copies of SEQ13 displayed on the surface of this particulate antigen promote the induction of a potent anti-HBs antibody response in mice, rabbits and cynomolgus monkeys. Sera and purified polyclonal IgG from the immunised animals neutralised HBV infection in vitro and mediated efficient HBV/hepatitis B virus surface antigen (HBsAg) clearance in the mice. CR-T3-SEQ13-based vaccination induced long-term suppression of HBsAg and HBV DNA in HBV transgenic mice and eradicated the virus completely in hydrodynamic-based HBV carrier mice. The suppressive effects on HBsAg were strongly correlated with the anti-HBs level after vaccination, suggesting that the main mechanism of CR-T3-SEQ13 vaccination therapy was the induction of a SEQ13-specific antibody response that mediated HBV/HBsAg clearance.

CONCLUSIONS

The novel particulate protein CR-T3-SEQ13 suppressed HBsAg effectively through induction of a humoural immune response in HBV-tolerant mice. This B cell epitope-based therapeutic vaccine may provide a novel immunotherapeutic agent against chronic HBV infection in humans.

Для цитирования: Zhang Tian-Ying, Guo Xue-Ran, Wu Yang-Tao, Kang Xiao-Zhen, Zheng Qing-Bing, Qi Ruo-Yao, Chen Bin-Bing, Lan Ying, Wei Min, Wang Shao-Juan, Xiong Hua-Long, Cao Jia-Li, Zhang Bao-Hui, Qiao Xiao-Yang, Huang Xiao-Fen, Wang Ying-Bin, Fang Mu-Jin, Zhang Ya-Li, Cheng Tong, Chen Yi-Xin, Zhao Qin-Jian, Li Shao-Wei, Ge Sheng-Xiang, Chen Pei-Jer, Zhang Jun, Yuan Quan, Xia Ning-Shao. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.. Gut. 2019. DOI: 10.1136/gutjnl-2018-317725.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.